Today's Daily Dose brings you news about regulatory progress of Aeterna's Macrilen; BioTelemetry's collaboration with Onduo; Catalyst Pharma's Lambert-Eaton myasthenic syndrome study results and stock offering; Dova's near-term catalyst, and Regeneron's setback in Eylea combo therapy.
from RTT - Biotech http://ift.tt/2jskMIg
via IFTTT
No comments:
Post a Comment